Little is known about the cell types or mechanisms that underlie the engraftment process. ؉ cells were capable of acting as ACs even though no repopulating cells are present. Cytokine treatment of NOD/SCID mice could partially replace the requirement for co-transplantation of AC. Furthermore, no difference was seen between the percentage of engrafted mice treated with cytokines for only the first 10 days after transplant compared to those receiving cytokines for the entire time of repopulation. Surprisingly, no engraftment was detected in mice when cytokine treatment was delayed until 10 days posttransplant. Together, these studies suggest that the engraftment process requires pluripotent stem cells plus accessory cells or cytokine treatment which act early after transplantation. The NOD/SCID xenotransplant system provides the means to further clarify the processes underlying human stem cell engraftment.
The most conclusive way to identify stem cells is to follow repopulation after transplantation. 1, 2 Clinically, it has been difficult to identify the factors and cell types that play a role in the engraftment process because of the absence of assays for human repopulating cells. Recently we have developed an in vivo assay for primitive human hematopoietic cells based on their ability to repopulate the bone marrow (BM) of NOD/SCID mice following intravenous injection. 3 The engrafting cell was operationally termed the SCID-repopulating cell (SRC). In this in vivo system, the engraftment of human cells after transplantation infers that the SRC must navigate to the mouse BM, survive in this microenvironment and then proliferate and differentiate extensively. Accumulated data from gene marking, cell purification, and kinetic analysis indicated that SRC are biologically distinct from and more primitive than most progenitors that can be assayed in vitro. [4] [5] [6] Similar approaches were taken to identify acute myeloid leukemia (AML) stem cells, termed SCID-leukemia initiating cells (SL-IC), based on their ability to establish leukemic proliferation in SCID and NOD/SCID mice. 7, 8 Although this xenotransplant system has allowed for the detection and purification of engrafting human stem cells that are undoubtedly relevant to clinical bone marrow transplantation, relatively little is known about the mechanism that underlies the engraftment process itself.
Available clinical data suggest that depletion of mature cells, such as T cells, from the transplanted BM decreases the rate and extent of donor cell engraftment. 9 In addition, autotransplants of BM which were combined with accessory cell populations such as those in peripheral blood demonstrated that reconstitution occurred earlier than if BM alone was used. This impairment in hematological recovery after depletion of cell fractions has lead to the hypothesis that a facilitating mechanism provided by a subpopulation of cells is required early in the engraftment process especially for allogeneic transplantation. 10 It has been difficult to conclusively establish the requirement and nature of these ACs in murine studies that involve syngeneic transplantation of highly purified murine stem cell populations into lethally irradiated recipients, since short-term repopulating cells must be co-transplanted to enable survival of the recipient. 1, 11 Highly purified subfractions found within CD34 ϩ populations are important clinically in autotransplants for multiple myeloma and breast cancer since recent studies indicate that cells enriched solely on the basis of CD34 expression may still be contaminated with tumor cells. 12, 13 In order to begin to better understand the processes involved in the engraftment of purified human stem cells, we have studied the roles of cytokine treatment and the cotransplantation of non-repopulating cell fractions of CB or BM on the engraftment potential of limiting cell doses of highly purified human hematopoietic cells. We report that in order for less than 1000 highly purified Lin Ϫ CD34 ϩ CD38 Ϫ cells from CB to engraft, the cotransplantation of accessory cells (ACs) or short-term treatment with cytokines were necessary. Facilitation of engraftment by AC in this xenotransplant model is not limited to normal stem cells, but is also required for the engraftment of purified CD34 ϩ CD38 Ϫ cells from AML patients. Co-administration of ACs and treatment with cytokines had no synergistic effect on the frequency of engraftment, and cytokine treatment alone was only required during the first 10 days after transplant. This study demonstrates that other components extrinsic to stem cells are required for successful engraftment and that this model will be a useful tool to identify the mechanism by which cytokines and ACs facilitate engraftment of human repopulating cells in patients.
Materials and methods

Human cells
Human BM cells were obtained from harvests of normal donors for allogeneic transplantation in accordance with procedures approved by the Human Experimentation Committee at the Ontario Cancer Institute (OCI), Toronto, Ontario. Samples of CB were obtained from discarded placental and umbilical tissues. BM and CB samples were diluted 1 to 3 in Iscove's modified Dulbecco's medium (IMDM; Gibco BRL, Burlington, Ontario, Canada) and enriched for mononuclear cells by centrifugation on Ficoll-paque (Pharmacia, Uppsala, Sweden). Leukemic peripheral blood specimens from patients with AML were obtained after informed consent according to procedures approved by the Human Experimentation Committee. AML samples were processed as previously described. 
Purification of cell populations
As depicted in Figure 1 , mononuclear cells were stained with a mixture of lineage specific antibodies (CD2, CD3, CD14, CD16, CD19, CD24, CD56, CD66b, CD41, glycophorin A) provided by the manufacturer (StemCell Technologies, Vancouver, BC, Canada), followed by addition of secondary antibody conjugated to metal colloid. Cells were then eluted through a magnetized column in order to enrich for cells not expressing lineage markers (Lin Ϫ ); the cells remaining on the column (Lin ϩ ) were then washed off the demagnetized column using phosphate-buffered saline (PBS) containing 5% FCS. As described previously, cell fractions were then stained with anti-hu CD34-fluorescein isothiocyanate (FITC) and anti-hu CD38-phycoerythrin (PE), and analyzed and sorted on a FACStar Plus (Becton Dickinson, San Jose, CA, USA) equipped with 5 W argon and 30 mW helium neon lasers. 6, 7 Fluorescence of FITC and PE excited at 482 nm (0.38 W) and 633 nm (30 mW), respectively, as well as known forward and side scatter properties of normal live human hematopoietic cells were used to establish sorting gates. Data acquisition and analysis were performed using LYSIS II software (Becton Dickinson).
Transplantation of purified cells into NOD/SCID mice
Eight-week-old NOD/LtSz-scid/scid (NOD/SCID) mice used in this study were bred from breeding pairs originally obtained from L Shultz (Jackson Laboratory, Bar Harbor, ME, USA), and maintained in the defined flora animal facility located at the OCI. All animals were handled under sterile conditions and maintained in micro-isolators. Purified cell populations, at the indicated dose, were transplanted by tail vein injection into sublethally irradiated mice (375 cGy using a 137
Cs ␥-irradiator) according to our standard protocol as previously described. 14, 15 Mice transplanted with purified Lin Ϫ CD34 ϩ CD38 Ϫ cells were cotransplanted with non-repopulating cells (ACs) and/or received alternate day intraperitoneal (i.p.) injections of human cytokines (huSCF 10 g, huIL-3 and huGM-CSF 6 g, from Amgen, Thousand Oaks, CA, USA). AC populations used were CD34 Ϫ cells derived from the Lin ϩ fraction, CD34
ϩ CD38 ϩ cells derived from the Lin Ϫ fraction, or mononuclear cells from CB and BM which had been irradiated (1500 cGy using a 137 Cs ␥-irradiator). Mice were killed 7-9 weeks after transplantation, and the BM from the femurs, tibiae and iliac crests of each mouse was flushed into IMDM containing 10% FCS.
Analysis of human cell engraftment in transplanted mice
Genomic DNA was isolated from the BM of transplanted mice by standard extraction protocols. 14, 15 EcoRI digested DNA was separated by agarose gel electrophoresis, transferred on to a positively charged nylon membrane and probed with a labeled human chromosome 17-specific ␣-satellite probe (p17H8). The level of human cell engraftment was determined by comparing the characteristic 2.7 kb band with those of human:mouse DNA mixtures as controls. Multiple exposures are performed to ensure sensitivity down to the limit of detection of 0.05% human DNA.
Results
Engraftment of low doses of Lin
Ϫ CD34 ϩ CD38 Ϫ
cells requires cytokine treatment and/or co-transplantation of accessory cells
To isolate populations enriched for SRC, CB cells were sorted based on CD34 and CD38 antigen expression as previously reported. 6 The SRC is found exclusively in the Lin 
5 Lin Ϫ CD34 ϩ CD38 ϩ cells injected alone did not engraft mice, confirming the absence of contaminating SRC in these two populations. 6 The results from 11 experiments with the four different treatment groups are summarized in Figure 2b . Similar to initial results, with the exception of one mouse, mice not treated with cytokines or co-transplanted with ACs were not engrafted with 500-1000 Lin Ϫ CD34 ϩ CD38 Ϫ cells. A lower percentage of engrafted mice (48%) was obtained with cytokine treatment alone vs co-transplantion with ACs (80%). However, the effects of cytokine treatment and co-transplantation ACs were not additive since the frequency of engraftment in mice that received both treatments was not different from that observed in mice that were co-transplanted with ACs alone (73% vs 80%). There was no significant difference in the level of engraftment or phenotype of human cells found in mice from the various treatment groups. Ϫ cells purified from a human CB sample with or without 1.0 ϫ 10 5 co-transplanted CD34 Ϫ cells. These two groups of mice were further separated into two groups in which one group received alternate day intraperitoneal injections of human cytokines (GF) until sacrifice. DNA from the BM of mice from these four groups was digested and probed for the presence of human engraftment. (b) Summary of the level of human cell engraftment from 82 mice from 11 experiments in which mice were transplanted with 500-1000 Lin Ϫ CD34 ϩ CD38 Ϫ cells purified from BM and CB with or without co-transplantation of Lin ϩ CD34 Ϫ cells (7.0 ϫ 10 3 to 2.0 ϫ 10
5
) and were treated with or without cytokines until sacrifice. Treatment groups are indicated along the horizontal axis.
Accessory cells are required for the engraftment of highly purified AML leukemic stem cells transplanted into NOD/SCID mice
To determine whether the requirement of ACs was common to both the normal and leukemic transplantation models, we transplanted limiting numbers of purified CD34 ϩ CD38 Ϫ cells from AML patients. We have previously reported that the cells in AML which are capable of engrafting SCID and NOD/SCID mice, termed SCID leukemia-initiating cells (SL-IC), were restricted to the CD34 ϩ CD38 Ϫ fraction and that this engraftment required administration of cytokines. 7 As shown in Figure 3 , in two different samples from patients with myelomonocytic (FAB M4) AML, both CD34 ϩ CD38 ϩ co-injection and cytokine treatment were required to obtain engraftment of 2000 or 1000 CD34
ϩ CD38 Ϫ cells. However, in contrast to normal SRC, low doses of transplanted CD34 ϩ CD38 Ϫ cells from AML patients did not engraft mice that were treated with cytokines in the absence of co-transplanted ACs. These experiments indicate that irrespective of the source of repopulating cells, ACs are required for human cell engraftment in NOD/SCID mice and that their facilitating effect is obligatory when transplanting low doses of highly purified AML cells even in the presence of cytokines. Figure 4 summarizes the frequency of engraftment in mice co-transplanted with these 4 different AC populations. Mice were transplanted with 1000 Lin Ϫ CD34 ϩ CD38 Ϫ CB cells on day 0 (n ϭ 5). In one group of mice, cytokine treatment began the following day and then every other day after transplant until mice were sacrificed at day 56. The other group was treated with cytokines for 10 days while the last group was treated starting at 10 days after transplant and continued to day 56.
Mature Lin
There was a trend towards co-transplanted Lin ϩ CD34 Ϫ and Lin
ϩ cells resulting in a higher level of engraftment than irradiated MNC from CB or BM. The frequency of engrafted mice was similar between all groups. Furthermore, irradiation of Lin ϩ CD34 Ϫ and Lin
ϩ cells did not affect the facilitating function of these populations (Figure 4 , open circles), demonstrating that the irradiation procedure does not affect the ability of any of these populations to act as ACs.
The effect of cytokines to facilitate engraftment is mediated only during the initial period following transplant
We have found that AC transplanted alone cannot be detected by DNA analysis (sensitivity of detection 0.05%) in the BM or other organs of transplanted mice when evaluated 10 days after the transplant suggesting that the facilitating effect occurs shortly after the transplant (data not shown). To determine whether another facilitating compo- nent such as cytokine treatment is also important only for the short term, we compared the frequency of engraftment when cytokines were given only for the first 10 days posttransplantation, for the entire period, or when cytokine treatment was delayed for 10 days after transplantation (Table 1) . In all cases the mice were transplanted with 800 Lin Ϫ CD34 ϩ CD38 Ϫ cells in the absence of ACs. The percentage of engrafted mice treated with cytokines for the first 10 days was similar to mice treated with cytokines for the entire experimental period (8-10 weeks), 54% and 48%, respectively (Table 1) . However, mice which did not receive cytokines for the first 10 days post-transplantation did not engraft even though cytokines were administered for the remainder of the experimental period (Table 1) . These data clearly demonstrate that cytokine treatment is only required for the first 10 days after transplantation of low numbers of purified human repopulating cells.
Discussion
The data reported here demonstrate that short-term cytokine treatment or co-transplantation of AC are required for engraftment of highly purified SRC. Similar treatments are also required for engraftment of SL-IC when highly purified AML cells are transplanted, suggesting that the mechanisms governing engraftment are not restricted to normal stem cells. Several different cell types can act as AC including Lin ϩ CD34 Ϫ cells, Lin Ϫ CD34 ϩ CD38 ϩ cells, and irradiated mononuclear BM or CB cells. While the precise mechanism of action of ACs is not known, the fact that cotransplantation of ACs can replace cytokines suggests that cytokine secretion from AC may be important. The fact that cytokines were required only during the first 10 days after transplant, concordant with the short-term presence of AC post-transplant supports the idea that cytokine treatment and AC co-transplantation may act via similar mechanisms. Furthermore, during hematopoietic recovery, mononuclear cells secrete more cytokines than those harvested during steady-state hematopoiesis and recent studies have demonstrated that cytokine levels are elevated following transplant, and coincide with hematological recovery. 18 Since mononuclear cells are known to be a source of cytokines during transplantation, it seems reasonable to ascribe a complementary role of ACs to the engraftment process by releasing cytokines in vivo.
Precisely how the cytokines and co-transplantation of ACs impact on SRC engraftment is unknown but could be both direct and indirect. Since the effect of both treatments was only short term, it appears that the action must target the SRC during the early phases of the transplant. We speculate that the cytokines could be inducing adhesion molecules on the SRC enabling efficient homing to the murine microenvironment. 19 Future studies should include detailed kinetic experiments where cytokines are given for different times and doses starting from before the transplant. Similarly the AC could be acting to prevent nonspecific homing. Only secondary transplantation of mice transplanted with the BM of donor mice which were recently transplanted with human stem cells would allow one to address whether cytokines or ACs affect homing of SRC. These experiments however are limited by our current difficulty in performing serial transplantation of human cells in NOD/SCID mice. Another mechanism by which cytokines and ACs may act is in promoting the survival of the SRC during early stages of the transplant. In this scenario, cytokine or AC function would be required only until enough human cells were produced that could produce selfsustaining amounts of the required cytokines. This hypothesis could explain why ACs are not required when high doses of SRC are transplanted.
We have shown previously that continuous cytokine treatment was required to generate high level human cell engraftment when human BM was transplanted into SCID mice. 15 In these studies, cytokines seemed to be stimulating the engrafting cells to proliferate and differentiate. However, it is difficult to compare the relationship between this previous work to the present study since these earlier studies involved transplantation of large cell doses which included a large number of Lin Ϫ CD34 ϩ CD38 ϩ and Lin ϩ CD34 Ϫ cells, cell types that we show here have facilitating function. Using the NOD/SCID recipients, high levels of engraftment could be achieved without cytokine treatment probably because these mice are more immunedeficient than SCID mice and their BM stroma environment is more permissive to human cell engraftment. 5, 20, 21 Since cytokines are required for less than 10 days post-transplant in NOD/SCID mice when highly purified cells are injected, we favor the idea that cytokine treatment promotes the survival and/or homing of the SRC in the early phase of the engraftment process. The fact that cytokine treatment is less effective than co-administration of ACs may be due to the presence of less than optimal conditions (concentration or cytokine combination) required to stimulate highly purified human stem cells. In addition, it is possible that cell-cell contact between Lin Ϫ CD34 ϩ CD38 Ϫ cells and ACs alone or in combination with mouse stroma is crucial for facilitating engraftment. ACs may have an advantage over cytokine treatment in that they are able to bypass these limitations.
Our studies indicate that both Lin ϩ CD34 Ϫ and Lin Ϫ CD34 ϩ CD38 ϩ cells have a comparable capacity to act as ACs. Clinical trials have found that T cell-depleted transplants were associated with a significant increase in the failure of engraftment. 22 These clinical data, as well as rodent models, suggested that T cells are required for engraftment of the BM stem cell in an allogeneic environment. 15, 23, 24 Transplantation of highly enriched or purified stem cell populations alone have been shown to suffer from the same limitations as the T cell depletion, ie failure of BM engraftment. This failure has been traditionally attributed to rejection by the host microenvironment. However, an alternative hypothesis to these observations is that a nonstem cell component in the donor BM may be required to facilitate stem cell engraftment in allogeneic recipients. Indeed, Ildstad's group 10 has reported the characterization of a bone marrow-derived cell that facilitates engraftment of allogeneic BM stem cells. This facilitating cell fraction was found to reside in the characteristic lymphoid gate and phenotypically defined to be CD8 ϩ CD3 ϩ TCR Ϫ CD45R ϩ class II dim. Like Lin Ϫ CD34 ϩ CD38 ϩ or Lin ϩ CD34 Ϫ cell fractions, as few as 10 000 of these cells were sufficient to facilitate engraftment. However, the fact that Lin Ϫ CD34 ϩ CD38 ϩ are derived from a population of cells depleted of lineage markers (including T cell markers) seems to indicate that the facilitating cell characterized by Ildstad's group differs from the AC populations characterized in our study. Recently, a parallel study from Verstegen et al 25 has demonstrated that SCID mice depleted of macrophages and transplanted with relatively high doses of CD34 ϩ
CD38
Ϫ cells produced 10-fold fewer CD34 ϩ cells in vivo compared to mice transplanted with equivalent numbers of unfractioned or purified CD34 ϩ cells suggesting that CD34
ϩ CD38 ϩ cells promote the expansion of the engrafting stem cells. 25 The co-transplantation of nonrepopulating CD34 ϩ CD38 ϩ cells with repopulating CD34 ϩ CD38 Ϫ cells was capable of restoring the graft size. Although the readout was different from our study (ie production of CD34 ϩ cells and not frequency of engrafted mice as we measured), these data support the idea that SRC, enriched in the CD34 ϩ CD38 Ϫ subset, require ACs that are found in the CD34 ϩ CD38 ϩ population. In conclusion, the results described here demonstrate the usefulness of the SRC assay to address issues regarding the complex process of human hematopoietic repopulation, and to elucidate the mechanism of action of accessory cells and/or cytokine treatment for the homing or survival of human stem cells.
